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Effects of thromboxane synthase inhibition with CGS 13080 in human
cyclosporine nephrotoxicity. Cyclosporine is a potent immunosuppres-
sive agent, however, its use is limited by nephrotoxicity. Increased
production of the potent vasoconstrictor thromboxane A2 contributes
to cyclosporine nephrotoxicity in animal models, but the role of
thromboxane in human cyclosporine nephrotoxicity has not been
established. We therefore studied cyclosporine-treated renal allograft
recipients who had evidence of toxicity manifested by decreased renal
function. We measured GFR and PAH clearance (CPAH) before, during,
and one week after a 48-hour intravenous infusion of the thromboxane
synthase inhibitor CGS 13080. At baseline, the urinary excretion of
TXB2 and 2,3-dinor-TXB, was elevated in the study patients compared
to healthy subjects. CGS 13080 infusion caused selective and nearly
complete inhibition of thromboxane metabolite excretion in all patients.
Mean CPAH improved 33% from 223 45 to 298 59 mI/min/m2 (P =
0.055) during infusion, while mean GFR improved 9% from 50.1 3.9
at baseline to 54.6 4.5mllmin/l .73 m2 (P = 0.111). The effect on GFR
occurred primarily in those patients taking calcium channel blockers.
The mean increase in GFR in these 5 patients was 10.0 2.8 versus
—1.0 2.8mI/minim2 in the remainder. We conclude that thromboxane
synthase inhibitors may be useful in attenuating the nephrotoxic effects
of cyclosporine following renal transplantation.
Cyclosporine is a potent immunosuppressive agent which is
extremely effective in suppressing rejection in kidney, liver,
pancreas, and bone marrow allografts [1]. Recent studies sug-
gest that cyclosporine may also be useful for the treatment of
autoimmune diseases [1]. Unfortunately, the clinical applica-
tions of cyclosporine have been limited by the frequent occur-
rence of nephrotoxicity [2, 3] and especially concern about the
potential for chronic irreversible renal injury [41.
Animal studies suggest that cyclosporine causes renal vaso-
constriction [5]. Although several potential mediators of this
effect have been proposed [2, 3], a number of animal studies
suggest that part of the renal vasoconstriction associated with
cyclosporine administration may be due to increased produc-
tion of thromboxane A2. For example, both urinary excretion of
Present address: N.1.D.R./National Institutes of Health, Bethesda,
Maryland USA.
Received for publication June 4, 1991
and in revised form August 28, 1991
Accepted for publication August 30, 1991
© 1992 by the International Society of Nephrology
thromboxane metabolites and thromboxane production by the
kidney are increased in cyclosporine-treated rats [6—10]. Fur-
thermore, treatment of these animals with either thromboxane
synthase inhibitors [7, 10] or thromboxane receptor antagonists
[11, 12] improves renal function. In humans, however, a role for
thromboxane in cyclosporine nephrotoxicity has not been dem-
onstrated.
The purpose of this study was to investigate the potential role
of thromboxane in human cyclosporine nephrotoxicity. We
studied a group of renal allograft recipients who were taking
cyclosporine as their primary immunosuppressive therapy. To
examine the role of thromboxane as a renal vasoconstrictor in
these patients, we evaluated the effects of short term adminis-
tration of the specific thromboxane synthase inhibitor CGS
13080 on renal function and eicosanoid excretion.
The structure of CGS 13080 is shown in Figure 1. This agent
has potency five to six orders of magnitude greater with respect
to thromboxane synthase than toward other enzymes involved
in the metabolism of arachidonic acid in a variety of in vitro
systems including bovine aortic, sheep seminal vesicle, and
human platelet preparations (CIBA-GEIGY, unpublished ob-
servations). In healthy human subjects, CGS 13080 has a rapid
onset of action and a half-life after oral administration of
approximately one hour [13]. However, its pharmacokinetics
and efficacy have not been previously evaluated in renal al-
lograft recipients.
Our results suggest that urinary excretion of thromboxane
metabolites is increased in patients taking cyclosporine and that
the renal vasoconstriction caused by cyclosporine in these
patients is mediated in part by enhanced production of throm-
boxane A2.
Methods
Patient selection
Adults who had undergone cadaveric renal transplantation at
the Duke University or Durham Veterans Affairs Medical
Centers within the previous 20 months were considered for
enrollment in the study. To be eligible, patients were required
to have been treated with cyclosporine for at least one month,
with a stable plasma creatinine level of 1.6 to 3.0 mg/dl. Specific
exclusion criteria included: clinical evidence of acute or ongo-
ing allograft rejection; females of childbearing potential; pres-
ence of serious systemic disease unrelated to the kidney; occult
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blood in the stool, thrombocytopenia or history of any disorder
associated with bleeding; inability to refrain from the use of
non-steroidal anti-inflammatory agents for two weeks prior to
and two weeks during the study; and elevated serum liver
enzymes. Written informed consent was obtained and the study
was approved by the Investigation Review Boards of both
participating hospitals.
Maneuver
Enrolled patients were admitted to the Clinical Research Unit
(CRU) at Duke University Medical Center. Throughout the
study, all medications (including cyclosporine) were continued
without a change in dose. While on the CRU, patients received
a 4 g sodium diet. Blood pressure was recorded at six hour
intervals and more frequently during administration of the
investigational drug. Urine was collected during consecutive
six-hour periods throughout hospitalization for the measure-
ment of eicosanoids and creatinine. Blood sampling was per-
formed using an 18 or 20 gauge intravenous catheter which had
been in place for at least 30 minutes.
On the morning after admission, an intravenous infusion of
DSW (the vehicle for CGS 13080) was begun at 40 mI/hr. The
following morning renal function was measured as described
below. After completion of these baseline clearance studies, an
intravenous infusion of CGS 13080 in D5W was begun and
increased to a dose of 0.5 mg/kg/hr (40 ml/hr). This dose was
chosen to provide maximal inhibition of urinary thromboxane
excretion on the basis of a pilot study.
After 42 hours of CGS 13080 infusion, renal function mea-
surements were repeated while the CGS 13080 infusion contin-
ued. After a total of 48 hours, CGS 13080 infusion was stopped
and blood for CGS 13080 level was sampled at frequent inter-
vals over the next 24 hours for pharmacokinetic analysis. One
week later, patients were readmitted to the CRU for repeat
measurement of renal function.
Renal function measurements
Using standard techniques, the urinary clearance of 1251
iothalamate was measured as an index of GFR [141 and the
urinary clearance of p-aminohippurate (CPAH) was determined
to estimate renal plasma flow [15]. After a breakfast lacking
protein, patients were given 15 mi/kg of water to drink over 60
minutes. Urine was collected by spontaneous voiding and
additional water was given to maintain urine flow >3 ml/min.
After this urine flow rate was established, a priming dose of
PAH (0.05 ml/kg of a 20% stock solution diluted to 50 ml) was
given intravenously followed by a continuous infusion of a 0.8%
PAH solution at 60 mI/mm. At the time of the PAH priming
dose, 0.2 MCi/kg of '251-iothalamate was injected subcutane-
ously. After an equilibration period of at least 60 minutes, the
first clearance period was begun. Each study consisted of three
consecutive clearance periods of 30 to 60 minutes. Blood
samples were drawn at the beginning and end of each period.
Plasma PAH concentration was determined by a standard
chemical assay [14], and '251-iothalamate concentration mea-
sured by gamma counter. Plasma values for each period were
calculated as the log mean of the bracketing values at the
beginning and end of each period. Clearances were calculated
using the standard formula UV/P, with each measurement
representing the mean of three periods. The data were normal-
ized for body surface area and expressed as mllmin/1 .73 m2.
Urine eicosanoid measurements
Urinary eicosanoids were measured by gas chromatography
and mass spectrometry. Ten ml samples of urine were acidified
with 0,4 ml of glacial acetic acid, placed on preconditioned
PrepSep-R C-18 columns (Fisher Scientific, Pittsburgh, Penn-
sylvania, USA), washed with 3 ml of 12% acetonitrile (ACN)
and eluted with 2 ml of ACN. The samples were dried and
redissolved in 1.25 ml of phosphate buffered saline (PBS)
containing 0.05 M KH,P04 and 0.15 M NaCI (pH 7.4).
Samples were loaded onto columns containing a mixture of
three immunoaffinity resins with selectivity for TXB2/2,3-dinor-
TXB2 and 6-keto-PGF1/2,3-dinor-6-keto-PGF1, (provided by
Dr. Daniel R. Knapp, Medical University of South Carolina,
Charleston, South Carolina, USA) and allowed to equilibrate
for 15 minutes. The samples were washed twice with 5 ml of
PBS and twice with 5 ml water, eluted with 4 ml of 95% ACN
and dried.
Derivatives of the eicosanoids were made using 50 .d 5%
diisopropylethylamine in ACN and SO d 25% pentafluoroben-
zyl bromide in ACN at 60°C for 10 minutes. Derivatives were
then made using 50 td of 2% methoxyamine HCI in pyridine at
60°C for one hour and redried. After dissolution in 1 ml of
methylene chloride, samples were loaded onto preconditioned
B&J Solid Phase System silica columns (Baxter Healthcare
Corp., Muskegon, Michigan, USA), washed with 2 ml of 1.5%
methanol in methylene chloride (vol/vol) eluted with 1 ml of 5%
methanol in methylene chloride and dried. Derivatives were
made using 50 d of N,O,-bis-(trimethylsilyl)trifluoroacetamide
containing 1% trimethylsilylchlorosilane at 60°C for 60 minutes
and redried.
Residues were dissolved in 25 .&d of n-dodecane and measured
by stable isotope-dilution assays by means of selective-ion
monitoring of the ratio of the compound to the m/z ion of the
deuterium labelled internal standard. Gas chromatography was
performed on a DB-17 fused silica column (30 m x 0.32mm i.d.,
0.15 m film thickness, J&W Scientific, Folsom, California,
USA). The carrier gas was hydrogen, at a head pressure of 15
psi. Splitless injections (2 d) were made at an oven temperature
of 180°C, which was programmed to increase to 230°C at
25°C/mm, held for nine minutes, increased to 236°C at 1 .0°CI
(CH2)5-COOH
Fig. 1. The structure of CGS 13080 (imidazo (1,5a) pyridine-5-hexanoic
acid).
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Table 1. Baseline characteristics
Race 9B/ 2W
Age years 44.6 11.9 (31, 60)
Weight kg 77.4 13.0 (55.0, 97.0)
Time since transplant months 6.9 5.2 (1.6, 19.2)
Serum creatinine mg/dl 2.1 0.5 (1.6, 3.0)
Cyclosporine dose mg/kg/day 5.1 1.8 (2.5, 9.6)
Data are presented as means SD (minimum, maximum).
mm, to 276°C at 4.4°C/mm and held for three minutes. Ei-
cosanoids were detected by negative chemical ionization mass
spectrometry using methane as the reagent gas. TXB2 and
6-keto-PGF1 were quantified by measuring the ratio of the
intensity of ions m/z 614/618; for 2,3-dinor-TXB, and 2,3-dinor-
PGF1,, m/z 586/590. Urinary eicosanoid concentrations were
determined by extrapolation from standard curves generated
for each eicosanoid and expressed as pg/mg creatinine (Cr).
Twelve hour urine collections were made by 34 healthy males
(taking no medication) to establish reference ranges for ei-
cosanoid excretion as determined by these assays.
Serum TXB2
Serum TXB2 was determined by radioimmunoassay. Samples
were collected in glass tubes with no additives, incubated at
37°C for one hour and centrifuged. Unlabelled TXB2 (Upjohn
Co., Kalamazoo, Michigan, USA) was dissolved in 10% ACN.
Dilutions of serum samples and TXB2 standards ranging from
0.072 to 18 ng/ml were made in a buffer containing 0.5 M
Tris-HC1 (pH 6.8), 0.9% NaCI, 0.3% bovine serum albumin,
0.05% NaN3 and 0.01 54 EDTA. Samples were assayed in
duplicate. The '251-methyl ester of TXB2 (Advanced Magnetics,
Cambridge, Massachusetts, USA) was added to all sample and
standard tubes. Rabbit antiserum to TXB2 (Advanced Magnet-
ics) was then added and the tubes were incubated for 16 hours
at 4°C. An excess of goat anti-rabbit antibody bound to para-
magnetic particles was then added. The antibody/antigen com-
plexes were separated using a magnetic rack (Ciba-Corning
Diagnostics, Walpole, Massachusetts, USA) and washed once.
Bound radioactivity was determined by gamma counter and
serum TXB2 levels determined by comparison with a standard
curve using four parameter logistic curve fitting.
Plasma CGS 13080
Blood samples for assay of CGS 13080 level were collected in
tubes containing lithium heparin and the plasma level deter-
mined by fluorometric detection after HPLC separation. Plasma
concentrations are expressed as ng/ml plasma.
Whole blood cyclosporine
Trough whole blood cyclosporine levels were determined by
a standard HPLC assay that is insensitive to levels below 50
ng/ml [161. For purposes of analysis, levels below this threshold
were considered to be 50 ng/ml.
Statistical analysis
Means are presented as the mean standard error of the
mean (sEM) except where noted. This study had 80% power to
detect an 18% change in GFR during treatment with CGS 13080
with a 5% chance of making Type I error. Hypothesis testing for
the primary outcomes of interest (GFR, CPAH, eicosanoid
levels) was performed using the paired f-test, after confirming
that the data approximated a normal distribution using the
Shapiro-Wilk test. An ambiguity in the recording of clearance
period times during the study drug infusion in one patient made
calculation of renal function parameters impossible in that case.
All other data from this patient are included in the analysis.
Results
Eleven male patients were studied. The etiology of end-stage
renal disease was hypertension in three patients, diabetes
mellitus, membranoproliferative glomerulonephritis and IgA
nephropathy in one patient each, and unknown in the remaining
five. Baseline characteristics of the study patients are shown in
Table 1.
Figure 2 shows urinary eicosanoid excretion for study pa-
tients during the baseline period compared with that of 34
healthy males. Urinary excretion of native, unmetabolized
TXB2 was significantly higher (P = 0.004) in cyclosporine-
treated renal allograft recipients (60 5 pg TXB2/mg Cr) than in
the controls (35 6). Likewise, excretion of 2,3-dinor-TXB2
was elevated (P = 0.025) in study patients (534 90 pg/mg Cr)
compared to controls (291 33). In contrast, the serum TXB2
levels were lower (P = 0.002) in patients at baseline (263 53
ng/ml) than in 12 healthy subjects (351 34). There were no
significant differences in the excretion of prostacyclin metabo-
lites between the study patients and healthy subjects.
Figure 3 shows mean urinary eicosanoid excretion before,
during, and immediately after the 48 hour infusion of CGS
13080. As seen in panels A and B, CGS 13080 rapidly and
effectively inhibited excretion of TXB2 and 2,3-dinor-TXB2 in
all patients. Excretion of thromboxane metabolites remained
suppressed until the infusion of CGS 13080 was stopped. Over
the 18 hours of study after the infusion was stopped, excretion
of thromboxane metabolites increased toward, but did not
reach pre-infusion levels. There was no apparent effect of CGS
13080 infusion on excretion of prostacyclin metabolites, as
shown in panels C and D of Figure 3.
Blood pressure and heart rate were stable throughout the
study protocol (Fig. 4) with no apparent change induced by the
study drug. Likewise, plasma cyclosporine levels were unaf-
fected by CGS 13080 (Table 2). Mean CGS 13080 level at steady
state was 1891 ng/ml, while the terminal half-time for the
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Fig. 2. Baseline urinary excretion of the native renal (A) and dinor (B)
metabolites of thromboxane and prostacyclin in 34 healthy males (open
bars) and 11 cyclosporine-treated renal allograft recipients (hatched
bars). Data are means 5EM. *P< 0.05; ** P<0.001 between groups.
TXB2 6-keto-PGF1e, 2,3,-dTXB2 2,3-d-6k-PGF1c,
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Fig. 3. Urina,y excretion of eicosanoids. Beginning and end of CGS
13080 infusion are indicated by arrows. A, TXB2; B, 2,3-dinor-TXB,; C,
6-keto-PGF15; D, 2,3-dinor-6-keto-PGF1a. Data are means SEM.
Fig. 4. Systolic and diastolic blood pressure in mm Hg (solid symbols)
and heart rate. Beginning and end of CGS 13080 infusion are indicated
by arrows. Data are means SEM.
Table 2. Effect of CGS 13080 on serum TXB2, urinary eicosanoids,
trough whole blood cyclosporine level (blood CsA), GFR and
clearance of PAH (CPAH)
Baseline
CGS
13080
1 week
post
Serum TXB2 pg/mi 263 53 12 4' 150 30
Urine TXB2 pg/mi Cr 60 5 10 3C 7b
Urine dTXB2 pg/mi Cr 534 90 67 15° 389 58
Urine 6-keto-POF1, pg/in! Cr 78 22 73 10 59 15
Urine d6-keto-PGF1,, pg/mi Cr 226 50 285 66 242 60
Whole blood CsA ng/mi 130 34 126 29 134 35
GFR mi/min/1.73 rn2 50.1 3.9 54.6 4.5 53.9 4.5
CPAH mi/rnin/J.73 m2 223 45 298 59 337 63
—40
Baseline CGS 13080 Baseline CGS 13080
Fig. 5. Percent change of PAH clearance (CPAH) (A) and GFR (B) at
baseline and during infusion of CGS 13080 in individuals. Patients
taking calcium channel blockers are indicated by solid circles. Square
symbols represent the patient who developed pyuria, hematuria, and
increased proteinuria during the infusion.
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One patient (indicated by square symbols in Fig. 5) developed
increased qualitative proteinuria with pyuria and hematuna
during infusion of CGS 13080, all of which were improved at the
one week follow-up visit. This patient went on, however, to
have an episode of acute rejection (without graft loss) three
months later. It is thus possible that this patient had smoldering
rejection at the time of the study. If this patient is withdrawn
from the analysis, the mean increase in CPAH for the remainder
—
______________________________________________
of the group was 88 35 mllmin (P = 0.034) and the mean
0 increase in GFR was 6 2 mI/mm (P = 0.024).Subgroup analysis showed that the effect on GFR occurred
Time, hours primarily in those patients who were taking a calcium channel
blocker as part of their antihypertensive regimen (indicated by
closed circles in Fig. 5). The mean increase in GFR during CGS
13080 infusion among the five patients taking calcium channel
blockers was 10.0 2.8 ml/min/1.73 m2 versus —1.0 2.4 for
the remainder. CPAH increased by a mean of 90 60 mi/minI
1.73 m2 in the calcium channel blocker group versus 59 37 indisappearance of the drug from plasma averaged 73.1 minutes.
At 24 hours after the infusion was stopped, CGS 13080 was
detectable in the plasma of only one patient.
Table 2 shows the renal function measurements before,
during and one week after CGS 13080 infusion, as well as the
corresponding eicosanoid data. CPAH increased by a mean of
33% during infusion of CGS 13080 compared to baseline (P =
0.055). As shown in Figure 5A, renal plasma flow improved in
8 of 10 patients during CGS 13080 treatment. There was not a
significant correlation between the changes in CPAH or GFR and
the percent inhibition of excretion of either TXB2 or its dinor
metabolite.
patients not taking calcium blockers.
Despite the short half-life of CGS 13080, serum TXB2 and
urinary thromboxane metabolite excretion were still signifi-
cantly suppressed one week after the drug was discontinued
(Table 2). In addition, the trend for improved renal function
persisted at one week post-drug for both mean GFR (P 0.090)
and CPAH (P = 0.061) compared to baseline.
Discussion
The arachidonic acid metabolite thromboxane A3 has several
biologic actions which may contribute to the pathogenesis of
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renal disease. In the kidney, thromboxane causes renal vaso-
constriction [17] and contraction of mesangial cells [18]. In
addition, platelet aggregation and release functions are stimu-
lated by thromboxane [19] and may play a role in promoting
glomerular cell proliferation in immune-mediated renal disease
[20]. Previous studies have suggested that enhanced production
of thromboxane may have a pathogenetic role in a number of
kidney diseases including: (1) ureteral obstruction [21, 22]; (2)
lupus nephritis [23, 24]; (3) renal allograft rejection [25—27]; (4)
experimental glomerulonephritis [28, 29]; (5) diabetic nephrop-
athy [30]; and (6) cyclosporine toxicity [6—12]. Thus thrombox-
ane A2 appears to be a part of a final common pathway for renal
injury in diseases of diverse etiology.
In the present study, urinary excretion of thromboxane
metabolites was elevated in cyclosporine-treated patients com-
pared to healthy controls. The significant increases in excretion
of both TXB2 and 2,3-dinor-TXB2 in the patient group were
very similar to our previous observations in rats given large
doses of cyclosporine [10]. Current evidence suggests that
native, unmetabolized TXB2 in urine reflects thromboxane
production by the kidney, while 2,3-dinor-TXB2 may primarily
reflect systemic thromboxane production [31, 32]. It is conceiv-
able that some portion of the increase in 2,3-dinor-TXB2
excretion in our patients might be attributable to elevated
platelet thromboxane production, since Jorkasky et al [33] have
previously reported increased production of thromboxane by
platelets exposed to cyclosporine. However, serum TXB2 lev-
els, which are a direct measure of platelet thromboxane pro-
duction, were actually lower in the patients we studied
compared to normal. This suggests that the increased 2,3-dinor-
TXB2 in our cyclosporine-treated patients might have derived
from non-platelet sources. We cannot rule out the possibility
that the native kidneys were in part responsible for the increase
in thromboxane metabolite excretion seen in our cyclosporine-
treated patients.
The marked decreases in urinary TXB2 and 2,3-dinor-TXB2
excretion and the reduction in serum TXB2 levels during
infusion of CGS 13080 reflect selective and nearly complete
inhibition of renal and systemic thromboxane production. It has
been suggested that the beneficial physiologic effects of selec-
tive thromboxane synthase inhibition may be due in part to
shunting of endoperoxides toward the synthesis of vasodilator
prostanoids [34]. In the present study, however, no increase in
prostacyclin metabolite excretion was observed during CGS
13080 infusion. Since cyclosporine levels and blood pressure
also did not change during the infusion, the observed improve-
ment in renal function can be attributed to the direct effects of
inhibition of thromboxane. Although the molecular mechanism
and reversibility of thromboxane synthase inhibition induced by
CGS 13080 are unclear, its effects on thromboxane production
persisted long after the drug had been cleared from plasma. For
up to one week after the infusion discontinued, both serum
TXB2 levels and urinary excretion of thromboxane metabolites
were reduced. In addition, one week after the infusion was
stopped CPAH and GFR remained numerically higher than at
baseline.
There are a number of potential causes of renal dysfunction in
the first twelve months following transplantation [35]. To re-
duce the chance that patients in the study might have renal
insufficiency related to rejection or causes other than cyclospo-
rifle nephrotoxicity, we selected patients with mild, yet stable
levels of renal dysfunction. By selecting only patients with
modest functional impairment, we may have excluded those
patients who would have benefitted most from the intervention.
Nevertheless, eight of the ten patients studied experienced
improvements in PAH clearance over the relatively short
period of drug administration.
This observation is in accord with a recent report by van der
Heide et al [36] showing improvement in renal function in
cyclosporine-treated renal allograft recipients given dietary fish
oil supplements, which reduce renal thromboxane production
[37]. In a study by Zipser [38], thromboxane synthase inhibition
did not affect inulin and PAH clearance in healthy subjects. In
addition, CGS 13080 has been given to more than 75 subjects
not taking cyclosporine without any discernible effect on the
serum creatinine (CIBA-GEIGY, unpublished observations).
Although our data provide suggestive evidence that acute
infusions of CGS 13080 may ameliorate cyclosporine nephro-
toxicity, thromboxane inhibitors may have other beneficial
effects following renal transplantation. Our group and others
have shown that thromboxane inhibition improves the course of
allograft rejection in animal models [25, 27, 39, 40]. In our
experience in these animal models [25, 40], the effects of
long-term treatment with thromboxane inhibitors are generally
greater than the effect of acute administration protocols such as
that utilized in this study. This current study clearly documents
the feasibility of attaining specific inhibition of thromboxane
synthesis in renal allograft recipients, and we are actively
evaluating the effects of prolonged administration of thrombox-
ane synthase inhibitors on transplant function.
The beneficial effect of CGS 13080 on GFR was most marked
in patients who were also taking calcium channel blockers.
Four of the five patients taking calcium channel blockers
experienced increases in GFR of a magnitude which would be
considered clinically significant. This is of interest in light of
previous reports that have demonstrated synergistic effects of
thromboxane synthase inhibitors and calcium channel blockers
on inhibition of platelet aggregation and platelet thromboxane
production [41, 42]. In addition, Loutzenhiser et al [43] were
able to block the effect of the thromboxane agonist U-44069 on
rat aortic rings and isolated perfused kidneys by pretreating
with diltiazem. Previous studies have suggested that pretreat-
ment with calcium channel blockers alone may protect against
cyclosporine nephrotoxicity [44]. Although the mechanism of
this effect is unclear, proposed explanations include direct
vasodilatation, protection of cell membranes from calcium
dependent phospholipid breakdown, and inhibition of intracel-
lular calcium accumulation [441. As GFR was improved more
than CPAH in patients in the present study who were taking
calcium channel blockers, it may be that the combined effect of
CGS 13080 and calcium channel blockade is to increase Kf by
inhibiting thromboxane-induced mesangial cell contraction. In
any event, our results suggest that the beneficial effects of
calcium channel blockers in cyclosporine nephrotoxicity may
relate to their antagonistic effects on the synthesis or actions of
thromboxane A2.
The two most common clinical syndromes of cyclosporine
nephrotoxicity can be broadly divided into acute reversible
renal vasoconstriction and chronic irreversible nephropathy [2,
3]. Acute cyclosporine nephrotoxicity is characterized by a
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reversible increase in renal vascular resistance associated with
reductions in both renal blood flow and glomerular filtration
rate. Generally, this acute syndrome is non-progressive, dose-
dependent and reverses with dose reduction or discontinuation
of the drug. Chronic cyclosporine nephropathy is defined by the
development of interstitial fibrosis and irreversible reduction in
renal function. Morphologically, chronic cyclosporine nephrop-
athy is characterized by focal or striped interstitial fibrosis with
tubular atrophy. Often these changes are accompanied by
obliterative arteriolar lesions. In some patients, this renal
fibrosis and loss of kidney function may be progressive [1—4]. In
addition to the vasoconstrictive properties of thromboxane,
recent studies have shown that thromboxane agonists can
stimulate the production of extracellular matrix proteins by
mesangial cells [45]. Thus, an enhancement of renal thrombox-
ane production by cyclosporine may promote the abnormal
accumulation of matrix proteins in the kidney. Therefore,
thromboxane may be involved in the pathogenesis of both the
acute vasoconstriction as well as the chronic renal injury
associated with cyclosporine nephrotoxicity. Moreover, it is
possible that long term administration of thromboxane inhibi-
tors may help prevent the development of renal fibrosis, which
is the most clinically important manifestation of cyclosporine
nephrotoxicity.
In summary, the results of this study suggest that renal
thromboxane production is enhanced in renal allograft recipi-
ents treated with cyclosporine. Administration of CGS 13080
caused nearly complete inhibition of renal and systemic throm-
boxane production. In this patient group, thromboxane syn-
thase inhibition tended to improve renal function, particularly
in patients taking calcium channel blockers. We conclude that
thromboxane synthase inhibitors may be useful in ameliorating
the nephrotoxic effects of cyclosporine following renal trans-
plantation.
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